Eidos Therapeutics, Inc., a San Francisco, CA-based clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), raised $64.0m Series B financing.
The round, which brings the total capital raised to approximately $91.0m, was led by RA Capital Management and included Eidos’ parent company, BridgeBio Pharma, in addition to new investors Janus Henderson, Viking Global Investors, Aisling Capital, Perceptive Advisors, Cormorant Asset Management and Amzak Health Investors. In connection with the financing, both Rajeev Shah, managing director and portfolio manager at RA Capital, and Eric Aguiar, MD, partner at Aisling Capital, will join Neil Kumar and Hoyoung Huh, MD, PhD, on Eidos’ board of directors.
The proceeds from the financing will be used to advance Eidos’ small molecule product candidate, AG10, into Phase 2 clinical trials and to continue preparations for Phase 3 clinical trials.
Led by Neil Kumar, PhD, chief executive officer, Eidos is advancing AG10, an orally-administered, small molecule designed to potently and selectively stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.